GRAd-COV2 vaccine provides potent and durable humoral and cellular immunity to SARS-CoV-2 in randomized placebo-controlled phase 2 trial.

Cell Rep Med · 2023 · PMC10243192 · PMID 37315558

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

did not reach statistical significanceno p-value reported

A representative sample of day 36 sera from 100 subjects per vaccine arm tested with spike pseudotyped vesicular stomatitis virus (VSV) ( Figure 3 E) returned GMs of 105.8 and 163.1 NT 50 for the SD and RD arms, respectively, on the Wuhan strain, a difference that did not reach statistical significance with sample numerosity reduced to one-third.

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.